Jubilant Life Sciences gains 4 per cent at closing hours

Jubilant Life Sciences’ material wholly owned subsidiary Jubilant Pharma through one of its wholly owned subsidiaries has received Abbreviated New Drug Application (ANDA) final approval

The United States Food and Drug Administration (USFDA) has granted the final approval for Clomipramine Hydrochloride Capsules USP 25mg, 50mg and 75mg, the generic version of Anafranil of SpecGx LLC. The mentioned drug is used for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD).

Jubilant had a total of 96 ANDAs for Oral Solids filed in the US, of which 61 had been approved and 15 Injectable filings, of which 13 had been approved (as on June 30, 2019).

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

The shares of Jubilant Life Sciences on Wednesday opened at Rs. 545.05 as against Tuesday’s close of Rs 541.30 per share on the BSE. At closing hours the stock was trading at Rs 567.30, gaining 4.80 per cent. The stock hit an intraday high of Rs. 575.25 and intraday low was Rs. 545.05. Its 52-week high was Rs. 898 and 52-week low was Rs. 392 per share on the BSE.